UNASSIGNED: This retrospective cohort study was conducted at King Saud University Medical City (KSUMC) from Jan 2017 to Feb 2023. The study included adult patients diagnosed with Candida infections who received ≥ 4 doses of echinocandins. Patients with body mass index (BMI) less than 18 kg/m2 were excluded from the study. The primary and secondary outcomes included the total length of stay (LOS), IC duration, frequency of clinical resolution and all-cause mortality.
UNASSIGNED: This study included 132 patients (47 obese; 85 non-obese) with a median age of 61 years. The median BMI and weight were different between the obese (34.5 kg/m2, 88 kg) and non-obese (24 kg/m2, 65 kg) groups (P= 0.01). Micafungin and caspofungin were used in 63.6% and 36.4% of patients, respectively. The total LOS and length of IC infections were similar between both groups, with median values of 29.5 days (P= 0.896) and 18 days (P = 0.160), respectively. The clinical improvement percentages were 68.1% for obese and 65.9% for non-obese patients (P= 0.797), with all-cause mortality rates at 44.7% and 42.4%, respectively (P= 0.796).
UNASSIGNED: The study found no clinical outcome differences between obese and non-obese patients, with Similar effectiveness of the echinocandins\' SDs in both groups. Further research in multi-centre settings is recommended to detect any potential differences between the two groups.
■这项回顾性队列研究于2017年1月至2023年2月在沙特国王大学医学城(KSUMC)进行。该研究包括诊断为念珠菌感染并接受≥4剂量棘白菌素的成年患者。体重指数(BMI)小于18kg/m2的患者被排除在研究之外。主要和次要结果包括总住院时间(LOS),IC持续时间,临床分辨率和全因死亡率的频率。
■这项研究包括132名患者(47名肥胖;85名非肥胖),中位年龄为61岁。肥胖(34.5kg/m2,88kg)和非肥胖(24kg/m2,65kg)组的BMI和体重中位数不同(P=0.01)。63.6%和36.4%的患者使用了米卡芬净和卡泊芬净,分别。两组的总LOS和IC感染长度相似,中位数分别为29.5天(P=0.896)和18天(P=0.160),分别。肥胖患者的临床改善百分比为68.1%,非肥胖患者为65.9%(P=0.797)。全因死亡率分别为44.7%和42.4%,分别为(P=0.796)。
■研究发现肥胖和非肥胖患者的临床结局没有差异,两组棘白菌素SDs的有效性相似。建议在多中心设置中进行进一步研究,以检测两组之间的任何潜在差异。